CAIM
PRME icon

Catherine Avery Investment Management’s Prime Medicine PRME Stock Holding History

Catherine Avery Investment Management’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-67
Closed -$196 – 177
2024
Q4 		$196 Buy
+67
New +$235 ﹤0.01% 171

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Catherine Avery Investment Management's PRME Position: Q1 2025 in Review

Catherine Avery Investment Management sold out of Prime Medicine (PRME) in Q1 2025, closing a stake of 67 shares — an estimated $196 sold.

Catherine Avery Investment Management first reported a position in PRME in Q4 2024 and held it in 1 quarter. The position peaked at $196 in Q4 2024. 125 funds tracked by Wall St. Rank hold PRME as of Q1 2025.

  • Catherine Avery Investment Management reported no remaining Prime Medicine position as of Q1 2025 after selling out during the quarter.
  • Catherine Avery Investment Management sold 67 Prime Medicine shares in Q1 2025, an estimated $196.
  • Catherine Avery Investment Management first reported a position in Prime Medicine in Q4 2024 and held it in 1 quarter.
  • Catherine Avery Investment Management's Prime Medicine position peaked at $196 in Q4 2024.
  • 125 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2025.

Based on Catherine Avery Investment Management's 13F filing for Q1 2025, filed 5 Jan 2026.